| Literature DB >> 24132133 |
Rachel L Peters1, Lyle C Gurrin, Shyamali C Dharmage, Jennifer J Koplin, Katrina J Allen.
Abstract
IgE-mediated food allergy is a transient condition for some children, however there are few indices to predict when and in whom food allergy will resolve. Skin prick test (SPT) and serum-specific IgE levels (sIgE) are usually monitored in the management of food allergy and are used to predict the development of tolerance or persistence of food allergy. The aim of this article is to review the published literature that investigated the predictive value of SPT and sIgE in development of tolerance in children with a previous diagnosis of peanut, egg and milk allergy. A systematic search identified twenty-six studies, of which most reported SPT or sIgE thresholds which predicted persistent or resolved allergy. However, results were inconsistent between studies. Previous research was hampered by several limitations including the absence of gold standard test to diagnose food allergy or tolerance, biased samples in retrospective audits and lack of systematic protocols for triggering re-challenges. There is a need for population-based, prospective studies that use the gold standard oral food challenge (OFC) to diagnose food allergy at baseline and follow-up to develop SPT and sIgE thresholds that predict the course of food allergy.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24132133 PMCID: PMC3823325 DOI: 10.3390/ijerph10105039
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Studies reporting on SPT and sIgE and the prognosis of PEANUT allergy.
| Author | N | Study design | Diagnosis of food allergy | Age 1 | Follow-up period | Follow-up diagnosis | Resolution | SPT (mm) | sIgE (kUA/L) |
|---|---|---|---|---|---|---|---|---|---|
| Mudd | 28 | Retrospective chart review | OFC | 5 years | 2.8 years (range 0.7–10 years) | OFC if clinically indicated (time, exposure and symptom history since last OFC or sIgE) | 46% | Not predictive of tolerance | |
| Ho | 267 | Longitudinal | SPT ≥ 4 mm | <2 years | Reviewed every 1–2 years for up to 8 years. | OFC offered when SPT < 4 mm (<2 years old) or 8 mm (>2 years old) | 18% | Increase SPT ≥ 3 between 1 and 4 years of age is predictor of persistence SPT ≥ 6 before 2 years predictive of persistent allergy | sIgE ≥ 3 before 2 years predictive of persistent allergy |
| Nolan | 54 | Prospective | Clinical history or positive SPT/sIgE with no history of ingestion. Excluded if sIgE >10 kUA/L, reaction in previous 2 years or previous severe reaction | 6.3 years (range 3.7–14.8 years) | NR | OFC (irrespective of SPT however parents could opt-out if SPT ≥ 8 mm | 53% | SPT ≥ 7 mm, 93% PPV | |
| Perry | 173 | Retrospective chart review | Clinical history or SPT/sIgE with no history of ingestion | 4.8 years | NR | OFC (if clinically indicated or when sIgE 25% of previously reported 95% PPV) | 59% | <2, 50% probability of tolerance | |
| (range 1–43 years) | |||||||||
| Fleischer | 84 | Retrospective chart review | Clinical history and SPT/sIgE or OFC; or no ingestion but positive SPT/sIgE | >4 years | NR | OFC or DBPCFC if sIgE < 5 | 55% | sIgE < 2 more likely to develop tolerance than sIgE 2–5 kU/L | |
| Skolnick | 223 | Retrospective follow-up | Clinical history and positive SPT, sIgE or OFC; or positive SPT and sIgE but no ingestion | 1.5 years (2 months–15 years) | NR | OFC. sIgE > 20 assumed allergic sIgE > 10 and severe reaction, no OFC (138 not challenged) | 21.5% | sIgE ≥ 5 64% PPV and 61% NPV | |
| Hourihane | 30 | Case-control | Clinical history | 5 years (range 2–10 years) | NR | OFC if clinically indicated (recent non-eventful exposure or negative SPT) | 50% | SPT ≥ 6 100% PPV and 80% NPV | Not predictive of tolerance |
| Sampson 1989 [ | 10 | Retrospective | DBPCFC | 7.9 years (range 3–18 years) | 1–3 years | DBPCFC or accidental ingestion | 20% | Not predictive of tolerance |
1 Age at diagnosis or entry into study; reported as mean or median (range); NR: not reported.
Studies reporting on SPT and sIgE and the prognosis of EGG allergy.
| Author | N | Study design | Diagnosis of food allergy | Age 1 | Period of follow-up | Follow-up diagnosis | Tolerance | SPT (mm) | sIgE (kUA/L) |
|---|---|---|---|---|---|---|---|---|---|
| Montesinos | 42 | Retrospective follow-up | Clinical history and positive SPT/sIgE and OFC | 15.7 months (range 8–27.5 months) | 49 months (range 15–118.6 months) | OFC annually unless reaction in previous 3 months and positive SPT/sIgE | 50% | ≤2 years: 1.37, 96% PPV 0.36, 66% NPV | |
| 2–3 years: 1.52, 100% PPV 0.54, 75% NPV | |||||||||
| 3–4 years: 1.35, 100% PPV 0.36, 75% NPV | |||||||||
| 4–5 years: 2.59, 100% PPV 0.96, 60% NPV | |||||||||
| >5 years: 1.84, 100% PPV 0.65, 100% NPV | |||||||||
| Dieguez | 157 | Retrospective follow-up | Clinical history and positive SPT or sIgE, or OFC | 2.5 years (range 1–16 years) | NR | DBPCFC | 36% | ≥7, 90% PPV, LR + 6.7 | ≥1.5 90% PPV, LR + 5.5 |
| ≥9, 96% PPV, LR + 12.3 | |||||||||
| Kim 2009 [ | 106 | Retrospective | sIgE > 2 | <2 years | Median 49 months (range 23–132 months) | Home challenge test if sIgE < 1.5 or accidental ingestion without reaction | 58% | Peak sIgE not predictive of outcome | |
| Mudd 2009 [ | 38 | Retrospective chart review | OFC | 5 years | 2.8 years | OFC when clinically indicated | 47% | Not predictive of tolerance | |
| Savage | 881 | Retrospective chart review | Clinical history or sIgE > 2 and no known exposure | 14 months (IQR 10, 23 months) | Median 59 months (range 5–285 months) | OFC if sIgE < 2 kUA/L | 68% | Rate of tolerance inversely related to peak sIgE. sIgE > 50 marker for persistent allergy | |
| Perry | 138 | Retrospective chart review | Clinical history or SPT/sIgE | NR | NR | OFC when clinically indicated or sIgE < 95% PPV | 57% | sIgE < 2 50% probability of tolerance | |
| Shek | 88 | Retrospective | DBPCFC | 6 months–17 years | Up to 10 years | DBPCFC | 32% | sIgE decrease by 50% in 12 months: 0.52 probability of tolerance | |
| sIgE decrease by 90% in 12 months: 0.78 probability of tolerance | |||||||||
| Boyano-martinez | 59 | Prospective | OFC (n = 35) or recent reaction and positive sIgE | <2 years | Median 32 months | OFC every 1–3 years depending on previous symptoms | 59% | SPT < 6 increased likelihood (HR) of tolerance by 3.74 (95% CI 1.60–8.74). | sIgE predicted tolerance only in children with cutaneous symptoms |
| Crespo | 40 | OFC | 1 year | 2.5 years | OFC | 38% | sIgE ≥ 1.2 kuA/L 92% PPV | ||
| Sampson 1989 [ | 59 | Retrospective | DBPCFC | 7.9 years (range 3–18 years) | 1–3 years | DBPCFC or accidental ingestion | 24% | Not predictive of tolerance | |
| Ford 1982 [ | 25 | DBPCFC | 17 months (range 6 months–10 years) | 2–2.5 years | OFC | 44% | Decreased in resolved allergy |
NR: not reported; IQR: interquartile range; HR: hazard ratio; 1 Age at diagnosis or entry into study; reported as mean or median (range).
Studies reporting on sIgE as a predictor of the prognosis of MILK allergy.
| Author | N | Study design | Diagnosis | Age 1 | Period of follow-up | Follow-up diagnosis | Tolerance | SPT (mm) | sIgE (kUA/L) |
|---|---|---|---|---|---|---|---|---|---|
| Yavuz 2013 [ | 148 | Retrospective | Clinical history, positive SPT/sIgE and either positive OFC or history of anaphylaxis | 1.6 years (IQR 0.9–3.1 years) | 3.5 years (IQR 1.8–5.2 years) | OFC if sIgE low and no recent reaction | 45% | Age-specific 95% PPVs to persistent allergy | |
| <1 years: 1.4 | |||||||||
| <2 years: 9.3 | |||||||||
| <4 years: 9.4 | |||||||||
| <6 years:11 | |||||||||
| All: 11 | |||||||||
| Suh 2011 [ | 115 | Retrospective | Clinical history and sIgE > 0.35; or sIgE > 5 | <24 months | Mean 47 months (range 24–114 months) | OFC or home introduction | 41% | Higher peak sIgE in first 24 months reduced probability of tolerance. | |
| Savilahti 2010 [ | 83 | Prospective birth cohort (n = 6,209) | Open OFC and SPT ≥ 3 mm or sIgE ≥ 0.7 | 7 months | Up to 8 years | OFC or home introduction | 78% | sIgE higher in those with persistent allergy | |
| Santos 2010 [ | 66 | Retrospective | OFC and SPT or sIgE | NR | Median 7 years | OFC if SPT or sIgE decreased and no recent reaction | 50% | Peak > 10 mm reduced the likelihood of tolerance (HR 0.38, 95% CI 0.14–0.99) | Higher maximum sIgE over time reduced the likelihood of tolerance |
| Martorell 2008 [ | 170 | Prospective | Clinical history or OFC, and SPT or sIgE | 5.4 months (1–12 months) | Up to 4 years of age | OFC if no reaction in previous 3 months | 82% | Age-specific 95% PPVs to persistent allergy | |
| 12 months: 5.86 | |||||||||
| 18 months: 9.79 | |||||||||
| 24 months: 25.7 | |||||||||
| 36 months: 7.38 | |||||||||
| 48 months: 5.0 | |||||||||
| Skripak 2007 [ | 807 | Retrospective review | Clinical history plus OFC or elimination diet | 13 months (range 1–209 months) | Median 54 months | OFC if sIgE < 2; or home introduction | 15% | Higher peak sIgE reduced probability of tolerance. | |
| Saarinen 2005 [ | 86 | Prospective birth cohort | Elimination challenge test | 7 months | Up to 8 years | Home challenge test or OFC | 85% | SPT 12 months after diagnosis: ≥7 mm AUC 0.84 | |
| Perry 2004 [ | 166 | Retrospective chart review | Clinical history or SPT/sIgE | NR | NR | OFC if clinically indicated | 45% | <2 50% probability of tolerance | |
| Garcia-Ara 2004 [ | 66 | Prospective | OFC | 4.8 months (range 1–11 months) | Mean 32.9 months (range 9–99 months) | OFC | 68% | Age-specific 95% PPVsto persistent allergy | |
| 13–18months: 2.7 | |||||||||
| 19–24months: 9 | |||||||||
| 26–36months: 24 | |||||||||
| Shek 2004 [ | 49 | Retrospective | DBPCFC | 34 months | Up to 10 years | DBPCFC | 33% | sIgE decrease of 50% in 12 months—0.31 probability of tolerance | |
| sIgE decrease of 90% in 12months—0.66 probability of tolerance | |||||||||
| Hill 1993 [ | 69 | Prospective | OFC or SPT | 20 months | Median 24 months | Home introduction or OFC at 5 years of age | 22% | Lower in transient allergy | |
| James 1992 [ | 29 | DBPCFC | 7 years (range 3–14 years) | Median 3 years | DBPCFC | 38% | Not predictive of tolerance | Not predictive of tolerance | |
| Sampson 1989 [ | 21 | Retrospective | DBPCFC | 7.9 years (range 3–18 years) | 1–3 years | DBPCFC or accidental ingestion | 19% | Not predictive of tolerance |
NR: not reported; HR: hazards ratio; 1 Age at diagnosis or entry into study; reported as mean or median (range).